On Jan. 14, AbbVie's (NYSE:ABBV) Rinvoq received approval from the U.S. Food and Drug Administration (FDA) to treat adults and children at least 12 years old with moderate-to-severe atopic dermatitis (eczema) whose condition didn't respond to other medicines.
What led the FDA to approve Rinvoq for its third indication? And how much of a boost could this be for AbbVie's sales? Let's dig into the phase 3 clinical trial results and U.S. moderate-to-severe eczema market to find the answers to these two questions.
Image source: Getty Images.
According to Healthline, eczema is a chronic skin condition often expressed by patches of dry, inflamed, and itchy skin. It's thought that the disease is caused by excessive production of immune system cells that lead to inflammation. Eczema typically begins in early childhood and flares up from time to time.
Common first-line treatments for the condition include antihistamines and topical corticosteroids (TCS). Unfortunately, a majority of patients with moderate-to-severe eczema (55%) cannot control their eczema with their current treatment regimen. This can result in sleep issues and weigh on a patient's quality of life, which is why there's demand for more treatments for the disease.
Fortunately, more treatment options are making their way to the market. One of those treatments is Rinvoq, which was approved last August in the European Union to treat moderate-to-severe eczema.What data is there to support the approval in the EU and most recently in the U.S.?
Rinvoq funded a randomized clinical trial of 901 moderate-to-severe eczema patients. These patients were blindly assigned to either receive 15 milligrams of Rinvoq once daily with TCS, 30 milligrams of Rinvoq each day combined with TCS, or a placebo pill and TCS. The patients were followed over the course of a 16-week period. The more pronounced the reduction in the Eczema Area and Severity Index (EASI), the more effective a treatment was for eczema patients. The EASI is a clinical scale that measures eczema's severity and surface area. A 75% or greater improvement in the EASI is called EASI75, which is the best indication of whether a treatment is effective enough to be approved by regulatory agencies.
Patients taking TCS and the lower dose of Rinvoq were found to have reached at least 75% clearer skin, or EASI75, at a 65% rate at week 16, which was much higher than the 26% rate for the TCS and placebo group at week 16. Even more striking, 77% of patients receiving the higher dose of Rinvoq achieved EASI75 at week 16.
Rinvoq could be a powerful treatment for many patients with eczema. So, what could this mean for pharma stock AbbVie?
First, it's estimated that there are 6.6 million adults in the U.S. with moderate-to-severe eczema. For the sake of conservatism and sparse data being available, I won't include the population of U.S. adolescents with the disease.
Second, although 55% of moderate-to-severe eczema patients aren't satisfied with their treatment plan, I'll assume that approximately 20% of the patient pool could start Cibinqo.This works out to 1.3 million potential patients.
Third, Cibinqo has the benefit of being a pill, which helps patients avoid having to go into clinics and hospitals for injections to treat their condition. On the other hand, the convenience of Cibinqo could be at least partially offset by the fact that the drug is a Janus kinase inhibitor. Due to the increased risk of serious adverse events like blood clots, cancer, and major heart-related issues, the FDA could end up restricting patients to just the lower dose of Cibinqo for safety reasons.
Considering all of these factors, I believe that the drug could capture 6% of the market, or 79,000 patients.
Rinvoq has an annual list price of $68,000. Adjusting for patient assistance programs and negotiations from health insurers, I'll use $20,000 as the net annual price per patient. This equates to just under $1.6 billion in annual revenue potential.
Against the $59.8 billion in revenue that analysts are forecasting for AbbVie this year, this would be a nearly 3% boost to the company's overall revenue. An additional $1.6 billion in annual revenue for AbbVie would represent a 30%+ increase in the company's non-Humira immunology segment revenue over the nearly $4.6 billion in combined Skyrizi and Rinvoq revenue for last year.
AbbVie's 8.5% increase in the dividends per share that it will pay out to shareholders in 2022 brings its dividend increase streak to 50 consecutive years -- including its time as part of Abbott Laboratories. This makes the stock a Dividend King.
AbbVie is trading at a forward price-to-earnings (P/E) ratio of 9.8, which is an appealing valuation considering that the stock's earnings are expected to grow 5% annually in the next five years. Investors can scoop up shares of AbbVie and its market-trouncing, steady 4.1% dividend yield on the cheap. That's what makes the stock an attractive option for income investors at the current $140 share price.
This article represents the opinion of the writer, who may disagree with the official recommendation position of a Motley Fool premium advisory service. Were motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.
More:
AbbVie Wins Yet Another Approval for This Drug - Motley Fool
- Retrospective analysis of 397 DABE | CCID - Dove Medical Press - December 3rd, 2023 [December 3rd, 2023]
- Derm In The News: November 26-December 2 - Dermatology Times - December 3rd, 2023 [December 3rd, 2023]
- When is the Best Time to Try Alternative Treatments for Eczema? - National Eczema Association - September 23rd, 2023 [September 23rd, 2023]
- How Eczema Negatively Impacted the Way She Talked to Herself - National Eczema Association - September 23rd, 2023 [September 23rd, 2023]
- Colloidal Oatmeal Effective in Improving Atopic Dermatitis in Black ... - Dermatology Times - September 23rd, 2023 [September 23rd, 2023]
- Combination Treatments in HS Require Further Review - Dermatology Times - September 23rd, 2023 [September 23rd, 2023]
- Addressing Misconceptions, Concerns Around Biosimilar Use - Dermatology Times - September 23rd, 2023 [September 23rd, 2023]
- Native American and Indigenous Communities Face Dermatologic ... - Dermatology Times - September 23rd, 2023 [September 23rd, 2023]
- Microwave Therapy Successful for Treating Warts in Children - Dermatology Times - September 23rd, 2023 [September 23rd, 2023]
- 9 Best Antifungal Body Washes Review - The Jerusalem Post - September 23rd, 2023 [September 23rd, 2023]
- Patients With Severe Psoriasis Have Higher Risk of Heart Disease ... - AJMC.com Managed Markets Network - September 23rd, 2023 [September 23rd, 2023]
- Swimming and skin: What to know if a child has eczema - Harvard Health - May 20th, 2023 [May 20th, 2023]
- Experts demand traffic-light labels to show strength of eczema cream - Daily Mail - May 20th, 2023 [May 20th, 2023]
- Its mosquito season. Here are tips for treating bites, preventing them in the first place - Yahoo News - May 20th, 2023 [May 20th, 2023]
- How new EU incentives will help all patients get the best treatments - Euronews - May 20th, 2023 [May 20th, 2023]
- Consistent Use of Ceramide-Containing Products Combined With ... - Dermatology Times - May 20th, 2023 [May 20th, 2023]
- The Best Swimming Skin and Hair Products | livestrong - Livestrong - May 20th, 2023 [May 20th, 2023]
- These 13 Household Items Contain Smells That Are Harmful To ... - Rock 92.9 - May 20th, 2023 [May 20th, 2023]
- FDA Approves First Pill to Treat Moderate-to-Severe Crohn Disease - HealthDay News - May 20th, 2023 [May 20th, 2023]
- Feds investigating eczema cream after two Oregon babies found with high levels of lead in blood - OregonLive - January 27th, 2023 [January 27th, 2023]
- Heres how to treat eczema and other skin conditions for cold weather - The Hindu - January 27th, 2023 [January 27th, 2023]
- Atopic eczema - NHS - November 23rd, 2022 [November 23rd, 2022]
- Seborrheic dermatitis - Symptoms and causes - Mayo Clinic - November 23rd, 2022 [November 23rd, 2022]
- Oatmeal skincare is the perfect solution for sensitive skin (+ best products to try) - Lifestyle Asia Singapore - November 23rd, 2022 [November 23rd, 2022]
- Eczema - StatPearls - NCBI Bookshelf - October 21st, 2022 [October 21st, 2022]
- Cold, dry weather can trigger eczema - how to reduce damage to the skin this winter - Express - October 21st, 2022 [October 21st, 2022]
- Eczema on lips nhs - kved.erxe.de - August 29th, 2022 [August 29th, 2022]
- xrfkc.vitalhaskap.pl - August 29th, 2022 [August 29th, 2022]
- Atopic eczema and alopecia areata - cyasn.kugel-lernfoerderung.de - August 29th, 2022 [August 29th, 2022]
- north shore zipline oahu - owk.tophouse.shop - August 29th, 2022 [August 29th, 2022]
- nak stock - vbi.maxense.shop - August 29th, 2022 [August 29th, 2022]
- Atopic eczema and alopecia areata - zayqif.hydra-market.shop - August 29th, 2022 [August 29th, 2022]
- fort worth map with zip codes - prxrzj.rids-gear.shop - August 29th, 2022 [August 29th, 2022]
- Ear Eczema: Symptoms, Causes, and Treatments - Healthgrades - August 29th, 2022 [August 29th, 2022]
- The Mutha Body Oil Is Worth the Splurge, Especially If You Have Sensitive Skin - POPSUGAR - August 29th, 2022 [August 29th, 2022]
- Are You Allergic to Your Beauty Products? A Patch Test Might Tell You - Allure - August 29th, 2022 [August 29th, 2022]
- Stinky sweat turns out to have a surprising health benefit : Goats and Soda - NPR - August 29th, 2022 [August 29th, 2022]
- Makeup for Eczema-Prone Skin: Considerations, Products, and Tips - Healthline - July 13th, 2022 [July 13th, 2022]
- Eczema Vaccinatum: Symptoms, Diagnosis, and Treatment - Healthline - July 13th, 2022 [July 13th, 2022]
- What Is Topical Steroid Withdrawal in Atopic Dermatitis Treatment? - Everyday Health - July 13th, 2022 [July 13th, 2022]
- A new 'cure for eczema' pill has been signed off but who is allowed to take it? - Cosmopolitan UK - July 13th, 2022 [July 13th, 2022]
- What Causes Dandruff And How To Get Rid Of It, According To A Dermatologist - Fatherly - July 13th, 2022 [July 13th, 2022]
- Allergies on the rise due to climate change - BusinessWorld Online - July 13th, 2022 [July 13th, 2022]
- Cryotherapy Treatment: Uses and Benefits - newschannelnebraska.com - July 13th, 2022 [July 13th, 2022]
- Mutations of Filaggrin Leading to Eggs & Milk Allergies - Physician's Weekly - June 18th, 2022 [June 18th, 2022]
- How AI & the Pandemic Are Changing the Skin & Hair Clinic Experience - The Quint FIT - June 18th, 2022 [June 18th, 2022]
- How to treat your childs dry skin in winter - Lowvelder - June 15th, 2022 [June 15th, 2022]
- Topical steroid: Types, uses, side effects and treatment as revealed by doctors - Hindustan Times - June 15th, 2022 [June 15th, 2022]
- Psoriasis in the Belly Button: Symptoms, Causes, and Treatment - Healthline - June 15th, 2022 [June 15th, 2022]
- In his last days, my father asked for Yiddish music - Forward - June 15th, 2022 [June 15th, 2022]
- Throwing away the water after cooking rice? Know how it could benefit your skin and hair - Times Now - June 15th, 2022 [June 15th, 2022]
- Family 'devastated and numb' as boy, 9, dies a day after breaking his arm - Coventry Live - June 15th, 2022 [June 15th, 2022]
- Happy Cappy Not Just For Babies; Everyone With Sensitive Skin Can Benefit - Pediatric Shampoo Granted Trademark in New Campaign: 'No Scalp Left... - June 15th, 2022 [June 15th, 2022]
- Eczema on black skin: Pictures, symptoms, and treatment - June 11th, 2022 [June 11th, 2022]
- Eczema on the Ears or Eyebrows: How to Cope - Everyday Health - June 11th, 2022 [June 11th, 2022]
- What People With Eczema Need to Know About Self-Screening for Skin Cancer - National Eczema Association - June 11th, 2022 [June 11th, 2022]
- How to protect children with eczema from scratching until they bleed - Channel NewsAsia - June 11th, 2022 [June 11th, 2022]
- Autism, allergies and other diseases and disorders afflicted baby boomers, too - PolitiFact - June 11th, 2022 [June 11th, 2022]
- Is saltwater good for the skin? What to know Beaufort South Carolina The Island News - The Island News - June 11th, 2022 [June 11th, 2022]
- What's trending? The most-read stories on APAC beauty market and consumer insights - CosmeticsDesign-Asia.com - June 11th, 2022 [June 11th, 2022]
- Canada to require a warning be printed on every cigarette - Coventry Live - June 11th, 2022 [June 11th, 2022]
- Holistic Acne Treatments That Are Better Than What You've Been Doing - The List - June 11th, 2022 [June 11th, 2022]
- Almirall: Eight out of Ten Patients Maintained Skin Clearance at One Year in Lebrikizumab Atopic Dermatitis Monotherapy Trials - PR Newswire UK - June 7th, 2022 [June 7th, 2022]
- Woman left balding and bedbound by chronic eczema clears the condition with a 9 face cream - The Independent - June 7th, 2022 [June 7th, 2022]
- Poll: Six in 10 people would eat food that has fallen on the floor - Coventry Live - June 7th, 2022 [June 7th, 2022]
- The itch that rashes: Treating and understanding eczema - El Paso Inc. - June 5th, 2022 [June 5th, 2022]
- Celebrities With Eczema Speak Out - Everyday Health - June 5th, 2022 [June 5th, 2022]
- Lotion, Cream, Gel, and Ointment Similarly Effective for Childhood Eczema - HealthDay News - June 5th, 2022 [June 5th, 2022]
- Antibiotics Given Before C-sections Are Not Linked to Asthma, Eczema in Young Children - Pharmacy Times - June 5th, 2022 [June 5th, 2022]
- Eczema Skin-Care Products Market Size, Scope and Forecast | Alliance Pharma Plc., Bausch Health Companies Inc., Bayer AG., AbbVie Inc., Eli Lilly and... - June 5th, 2022 [June 5th, 2022]
- What are the benefits of ceramides for the skin? - Medical News Today - June 5th, 2022 [June 5th, 2022]
- Some Allergies Associated With Lower Risk of SARS-CoV-2 Infection - Smithsonian Magazine - June 5th, 2022 [June 5th, 2022]
- The CDC is sending monkeypox vaccines to people at high risk in a race to prevent the spread - CNBC - June 5th, 2022 [June 5th, 2022]
- Missing Sikeston teen may be heading to Kansas City area - KMBC Kansas City - June 5th, 2022 [June 5th, 2022]
- Should you cleanse or exfoliate first? What to know - Medical News Today - June 5th, 2022 [June 5th, 2022]
- Dry Skin: Eczema, Itchy Skin, Causes, Treatments, Relief, Types - May 17th, 2022 [May 17th, 2022]
- Foods to Eat and Foods to Avoid If You Have Eczema - The Beet - May 17th, 2022 [May 17th, 2022]
- 3 Women With Eczema Describe the Ways They Combat Nighttime Flare-Ups - Verve Times - May 17th, 2022 [May 17th, 2022]
- The Challenges of Parenting a Child With Eczema - Verve Times - May 17th, 2022 [May 17th, 2022]
- Manuka Honey Benefits for Skin: Benefits, Masks, and More - Greatist - May 17th, 2022 [May 17th, 2022]